BioLineRx Ltd.
BLRX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001498403
No open-market purchases or sales by BioLineRx Ltd. insiders were filed in the last 90 days; 14 institutions reported holding it in 13F filings for Q2 2026, worth $206.7K in total; no superinvestor holds it.
13F holders, Q2 2025
Institutional positions in BioLineRx Ltd. as of Jun 30, 2025. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 17
- +5 vs. Q1 2025
- Shares held
- 66.2K
- +56.8K (+600.0%) vs. Q1 2025
- Total value
- $302.1K
- +$274.1K (+979.1%) vs. Q1 2025
- New holders
- 9
- 1 more added
- Sold out
- 4
- 3 more reduced
Compare with Q1 2025: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting BLRX on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 14 | $206.7K |
| Q1 2026 | 13 | $45.2K |
| Q4 2025 | 14 | $135.6K |
| Q3 2025 | 14 | $104.3K |
| Q2 2025 | 17 | $302.1K |
| Q1 2025 | 12 | $28.0K |
| Q4 2024 | 32 | $435.9K |
| Q3 2024 | 32 | $1.34M |
| Q2 2024 | 31 | $2.42M |
| Q1 2024 | 28 | $1.47M |
| Q4 2023 | 29 | $1.75M |
| Q3 2023 | 29 | $2.46M |
| Q2 2023 | 26 | $1.97M |
| Q1 2023 | 20 | $2.91M |
| Q4 2022 | 18 | $3.37M |
| Q3 2022 | 28 | $10.3M |
| Q2 2022 | 28 | $1.36M |
| Q1 2022 | 26 | $1.99M |
| Q4 2021 | 30 | $5.09M |
| Q3 2021 | 30 | $6.69M |
| Q2 2021 | 30 | $4.01M |
| Q1 2021 | 29 | $13.5M |
Institutions, Q2 2025
Shares, value and share of portfolio for each institution holding BioLineRx Ltd.; share changes are against Q1 2025.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Advisor Group Holdings, Inc. | 1 | $4 | 0.00% | +1 | New |
| Bank of America Corp | 2 | $9 | 0.00% | 00.0% | Unchanged |
| Danske Bank A/S | 2 | $9 | 0.00% | 00.0% | Unchanged |
| SBI Securities Co., Ltd. | 2 | $9 | 0.00% | 00.0% | Unchanged |
| Fifth Third Bancorp | 25 | $114 | 0.00% | +25 | New |
| Raymond James Financial Inc | 72 | $329 | 0.00% | +72 | New |
| GWM Advisors LLC | 107 | $489 | 0.00% | 00.0% | Unchanged |
| National Bank of Canada | 200 | $914 | 0.00% | +200 | New |
| Nemes Rush Group LLC | 250 | $1.14K | 0.00% | −50−16.7% | Reduced |
| Morgan Stanley | 1,543 | $7.05K | 0.00% | −701−31.2% | Reduced |
| Wells Fargo & Company | 1,750 | $8.00K | 0.00% | −1,250−41.7% | Reduced |
| Citigroup Inc | 4,005 | $18.3K | 0.00% | +4,005 | New |
| Rhumbline Advisers | 4,275 | $19.5K | 0.00% | +2,745+179.4% | Added |
| Susquehanna International Group, LLP | 11,098 | $50.7K | 0.00% | +11,098 | New |
| Two Sigma Securities, LLC | 13,816 | $63.1K | 0.01% | +13,816 | New |
| Simplex Trading, LLC | 14,114 | $64.0K | 0.00% | +14,114 | New |
| Citadel Advisors LLC | 14,954 | $68.3K | 0.00% | +14,954 | New |
| BNP Paribas Arbitrage, SA | 0 | $0 | 0.00% | −1,748−100.0% | Sold out |
| JPMorgan Chase & Co | 0 | $0 | 0.00% | −375−100.0% | Sold out |
| Group One Trading, L.P. | 0 | $0 | 0.00% | −79−100.0% | Sold out |
| UBS Group AG | 0 | $0 | 0.00% | −71−100.0% | Sold out |